A Study to Evaluate ITCA 650 for the Treatment of Type 2 Diabetes

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2013
Phase 3 study to examine whether treatment with ITCA-650 60 mcg/day or 40 mcg/day is superior to placebo when added to current therapy in reducing HbA1c in patients with type 2 diabetes.
Epistemonikos ID: ffce9fe04fe5c0a6116a6cf9bbc1b884b157d220
First added on: Mar 26, 2024